top of page
CONNECT
Let science do the talking
HOME
Our Approach
Leadership
Advisors
CSR
Academic Alliances
Licensing & Partnership
SCIENCE
Runaway Immune Response
Neuroinflammation
Immune Oncology
Vaccine Adjuvants
Acetate Metabolism
RESEARCH
Current Programs
Pipeline
Our Publications
NEWSROOM
CAREERS
CONTACT US
More
Use tab to navigate through the menu items.
O
ur
P
ipeline
Mechanism
Indication
Pre-clinical Candidate
Phase I
Phase II
Cancer
STING Agonist
All tumors
HPK1 Inhibitor
Solid tumors
Inflammation
STING Antagonist
Fibrotic disease
Neuroinflammation
Auto-immune disease
TNIK
Fibrotic disease
CLK/DYRK
Osteoarthritis
bottom of page
